Medpace Holdings Inc vs MGM Resorts International — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while MGM Resorts International trades at $46.49 (market cap $11.86B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MGM | |
|---|---|---|
Market Cap | $15.08B | $11.86B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $50.69 |
52-Week Low | $308.88 | $30.72 |
Enterprise Value | $14.55B | $40.90B |
Dividend Yield | — | 0.03% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
MGM Resorts International (MGM) trades at $46.55, up 0.91% today, amid ongoing acquisition talks with Barry Diller's People Inc. at $48.30 per share. The stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, revenue grew to $17.54B in 2025, though net income margin compressed to 1.03%. Analyst consensus is evenly split between Buy and Hold, with a $48.93 price target suggesting modest upside from current levels.
MGM's outlook is clouded by acquisition uncertainty and declining profitability, offset by potential takeover premium and stable revenue. Key risks include execution on margin improvement, high debt levels, and macroeconomic sensitivity. The stock presents a speculative opportunity tied to deal completion, with fundamental challenges requiring careful monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →